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Abstract
Background: HIF2α/EPAS1 is a hypoxia-inducible transcription factor involved in catecholamine
homeostasis, vascular remodelling, physiological angiogenesis and adipogenesis. It is overexpressed
in many cancerous tissues, but its exact role in tumour progression remains to be clarified.
Methods: In order to better establish its function in tumourigenesis and tumour angiogenesis, we
have stably transfected mouse neuroblastoma N1E-115 cells with the native form of HIF2α or with
its dominant negative mutant, HIF2α (1–485) and studied their phenotype in vitro and in vivo.
Results: In vitro studies reveal that HIF2α induces neuroblastoma cells hypertrophy and decreases
their proliferation rate, while its inactivation by the HIF2α (1–485) mutant leads to a reduced cell
size, associated with an accelerated proliferation. However, our in vivo experiments show that
subcutaneous injection of cells overexpressing HIF2α into syngenic mice, leads to the formation of
tumour nodules that grow slower than controls, but that are well structured and highly
vascularized. In contrast, HIF2α (1–485)-expressing neuroblastomas grow fast, but are poorly
vascularized and quickly tend to extended necrosis.
Conclusion: Together, our data reveal an unexpected combination between an antiproliferative
and a pro-angiogenic function of HIF2α that actually seems to be favourable to the establishment
of neuroblastomas in vivo.
Background
Cellular responses to low oxygen tension are mainly
mediated by the activation of heterodimeric transcription
factors, called hypoxia inducible factors (HIFs), which
consist of a constitutively expressed subunit (ARNT) and
an oxygen-regulated subunit, mainly HIF1α and HIF2α
(or EPAS1). Under normoxia, HIFα are subjected to enzy-
matic proline hydroxylation that target them for proteas-
ome degradation via the von Hippel-Lindau (VHL)
ubiquitin E3 ligase complex (for review, see [1]).
Both HIFs are overexpressed in many cancer cells and
mainly associated with invasiveness, poor prognosis and/
or tumour angiogenesis (for review, see [2]). Experimental
studies have however led to discrepant results regarding
their role in cancer, pointing to functions varying depend-
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ing on the cell type. Experiments performed with HIF1α-/
- embryonic stem (ES) cells conflictingly revealed that
HIF1 may act as a positive regulator of tumour growth,
most likely through its activation of vascular endothelial
growth factor (VEGF) expression [3] or as a negative regu-
lator, possibly through the stabilization of p53 in hypoxic
cells [4]. In pancreatic cancer, disruption of HIF1 pathway
using a dominant negative strategy reduces tumourigene-
sis [5]. Opposite results have also been obtained concern-
ing HIF2α. In renal carcinoma cells originating from
patients affected by Von Hippel Lindau disease, the
abnormal stabilization of HIF2α appears to be directly
responsible for tumourigenesis [6,7]. In teratomas derived
from ES cells carrying an HIF2α knock-in at the HIF1α
locus, Covello et al recently observed an increase in both
vascular density and proliferation [8]. In contrast, trans-
fection of HIF2α in a breast cancer cell line inhibits
tumour growth, both in vitro and in vivo [9], while it was
recently demonstrated to display pro-apoptotic activities
in both rat gliomas and ES cells-derived teratomas [10].
Neuroblastomas are highly vascularized tumours that
constitute one of the most frequent solid malignancy of
childhood. They arise from immature cells derived from
the neural crest and are particularly sensitive to low oxy-
gen tension. Hypoxic treatment of neuroblastoma cells
leads to their dedifferentiation towards a neural crest phe-
notype [11], while overexpression of VHL leads to their
differentiation into functional neuron-like cells [12].
Moreover, hypoxia was associated with an increased inva-
siveness of these tumours in vivo [11]. These data point to
a role of the HIF pathway in the induction of neuroblast-
oma's tumour phenotype.
HIF2α plays an important role in the sympathetic nervous
system (SNS), both during embryogenesis [13] and in
pathological conditions where it is associated with pheo-
chromocytoma malignancy [14]. Hence, it appeared per-
tinent to assess its role in the SNS-derived model of
neuroblastoma C1300. We thus carried out stable trans-
fection of these cells with HIF2α cDNA or with its domi-
nant negative mutant HIF2α(1–485) and show that
HIF2α displays antiproliferative but pro-angiogenic activ-
ities that favour the establishment of neuroblastoma nod-
ules in vivo.
Methods
Vector constructions
pCDNA3.1-EPAS1 vector, encoding human HIF2α cDNA
(1–870) was a gift from S. McKnight. HIF2α (1–485)
cDNA was amplified from pCNDA3.1-EPAS1 plasmid
using the elongase polymerase with the following prim-
ers: forward, 5'-GCCTCGAGCGACAATGACAGCT-
GACAAGGAGAAGAAAAGG-3' and reverse, 5'-
GCGGATCCTAGCTATTGGGCGTGGAGCAGCTGCT-
GCT-3', and cloned into PCRII-TOPO (Invitrogen).
HIF2α (1–485) cDNA fragment was then recovered by
HindIII-XbaI digestion and subcloned into pCDNA3.1
vector (Invitrogen).
Cell culture and stable transfections
Murine adherent neuroblastoma C1300 cells (clone N1E-
115, a gift from N. Lamandé, INSERM U36/U833, Paris,
France) were grown in 10 cm petri dishes in DMEM con-
taining 4.5 g/L glucose (Invitrogen) supplemented with
10% foetal bovine serum (Hyclone) and 2% antibiotics;
penicillin and streptomycin (Invitrogen). N1E-115 cells
were transfected using Lipofectin transfection reagent
(Invitrogen), as described by the manufacturer. Trans-
fected cells were selected with G-418 (750 μg/ml;
Geneticin; Invitrogen) and cloned by a limiting dilution
method.
RT-PCR
Total RNAs were isolated using the RNeasy extraction kit
(Qiagen) and reverse transcribed using random hexamers
and the MMLV reverse transcriptase (Invitrogen) as
described by the manufacturer. PCR reactions were per-
formed as follows: cDNAs were denatured (94°C for 5
min), submitted to 30 cycles of amplification (94°C for 1
min, Tm°C for 1 min and 72°C for 1 min) and to a final
elongation (72°C for 10 min). Primer sequences and Tm
used are available upon request.
Proteins assays
Cells were lysed in Laemmli buffer and 25 to 100 μg of
proteins used for Western blot analyses. PVDF mem-
branes were probed with a rabbit polyclonal anti-Tyrosine
hydroxylase (1:1000; Institut Jacques Bois), a rabbit poly-
clonal anti-HIF1α (1:3000, a generous gift from Dr. Dar-
ren Richard), anti-phospho-specific Akt IgG (1:1000),
anti-phospho-p70 S6 Kinase (Thr389) IgG (1:1000; Cell
Signaling Technology) or anti-p42/44 MAPK IgG (1:1000;
New England Biolabs). Membranes were subsequently
stripped in NaOH and probed with anti-Akt IgG (1:1000,
Cell Signaling Technology) and anti-p70 S6 kinase IgG
(1:200, sc-230; Santa Cruz). Immunoreactive bands were
visualized by enhanced chemiluminescence, digitized
using a 2-dimensional gel scanner, and quantified using
Quantity One software (Bio-Rad). For HIF2α western
blot, proteins were extracted using the NE-PER Nuclear
and Cytoplasmic Extraction Reagents (Pierce). 75 μg of
nuclear extracts were blotted on PVDF membranes and
probed with the ep190b anti-human HIF2α antibody
(1:500; abcam).
In another set of experiments, the release of VEGF by
native and transfected N1E-115 cells under normoxia and
reduced oxygen tension was measured using the murineBMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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VEGF development ELISA kit (PeproTech) according to
the manufacturer's instruction.
Cell size evaluation
Cell diameter was evaluated using the Adobe Photoshop
software. In vitro, cells were seeded at low confluence in 10
cm Petri dishes, in order to avoid the formation of cell
aggregates, and grown as described above. For each clone,
10 pictures were taken using a Sony Exwave HAD video
camera connected to an Olympus CK2 microscope. In
each field, 5 cells were randomly selected and their diam-
eter was measured. This study was repeated once, for a
total of 100 cells measured for each clone. For the in vivo
measurements, the diameter of cells was measured on his-
tological pictures of tissue sections stained with Masson's
Trichrome (see Histology and immunohistochemistry section).
For each clone, 15 cells form 3 different nodules were ana-
lysed, for a total of 50 cells per clone.
In vitro proliferation assay
500 000 cells were seeded in 10 cm Petri dishes. After few
hours, medium was replaced and the number of surviving
cells (T = 0) evaluated by using a Coulter counter (Beck-
man Coulter). Further counting was performed after 72,
96, 120 and 144 h. The relative proliferation rate of each
clone was assessed by calculating the slope of each prolif-
eration curve. This study was performed four times within
few weeks of interval.
In vivo tumourigenesis assay
Sixty five 8 weeks-old, female A/J mice, were purchased
from Jackson Laboratory and bred under standard condi-
tions at the Experimental Animal Center of our Research
center. Tumours were established in accordance to the
guidelines set by the Montreal Heart Institute (MHI) ani-
mal care committee and the Canadian Council for Animal
Protection. Each mouse was submitted to one injection of
2 × 106 cells in 500 μl Matrigel (Becton Dickinson). Injec-
tions were performed subcutaneously at one site on the
back of the mouse. The growth of tumour nodules was
then measured bidirectionally every 2 days and tumour
volume was calculated by the formula π/6 length2  ×
width. Mice were sacrificed 4 weeks after inoculation. For
four HIF2α expressing cells, the MHI ethical committee
allowed us to pursue our study up to day 35 post-inocula-
tion.
Histology and immunohistochemistry
Tumours were resected and fixed for 24 h at room temper-
ature, either in formalin or, for CD31 immunohistochem-
istry (IHC), in IHC zinc fixative (BD Biosciences
Pharmingen). Samples were then dehydrated and embed-
ded in paraffin and six μm-thick sections were submitted
to Masson's trichrome staining. Briefly, after treating tis-
sue sections with Bouin's solution to intensify the final
coloration, nuclei were stained with Weigert's iron hema-
toxylin, and cytoplasm and muscle with Beibrich scarlet-
acid fuchsin. After treatment with phosphotungstic and
phosphomolybdic acid, collagen was demonstrated by
staining with aniline blue [15].
Immunohistochemistry was performed as previously
described [16] with a rat anti-mouse CD31 (PECAM-1)
monoclonal IgG (MEC13.3, BD Biosciences Pharmin-
gen), a rabbit polyclonal anti-proliferating cell nuclear
antigen (PCNA) IgG (FL-261, Santa Cruz Biotechnology),
or an anti-cleaved caspase-3 (Cell signaling technology).
Determination of tumour vessel density
The number of blood vessels was quantified on Masson's
trichrome stained sections. For each sample, the number
of blood vessels was counted in 7 fields of 385 μm2 each,
in a blinded manner.
Statistical analyses
Statistical analyses were performed using the InStat® soft-
ware. Differences in cell size were evaluated by unpaired
t-test and variations in cell proliferation by a paired t-test.
In vivo growth of tumours and vascular density differences
were assessed by a Mann-Whitney test. A p value < 0.05
was considered significant.
Results
Establishment and characterization of the cellular models
We studied HIF2α 's function in the mouse model of neu-
roblastoma C1300 (N1E-115 clone). To better character-
ize these cells, we performed RT-PCR experiments to seek
for the expression of genes of interest (Fig. 1a). We
observed that N1E-115 cells express both HIF1α and
HIF2α, their common target genes VEGF and adrenom-
edullin as well as several neuroblastoma classical markers
including neuropilin-1, neuronal-specific enolase, Id2
and chromogranin A.
We then stably transfected N1E-115 cells with plasmids
encoding human HIF2α or its dominant negative mutant
(DN). HIF2α DN (namely HIF2α(1–485)) comprises the
DNA binding domain and the HLH-PAS dimerization
domains, but lacks both transactivation domains (Fig.
1b). All commercially available anti-HIF2α antibodies tar-
get the C-terminus of the protein, which happens to be
deleted in HIF2α(1–485). Screening for transfectants was
thus performed by RT-PCR using primers specific to the
human HIF2α sequence (Fig. 1c, upper panel). To avoid
unspecific responses due to clonal selection, we selected
two clones expressing HIF2α (E1 and E2) and two clones
expressing HIF2α(1–485) (DN5 and DN8). Western blot
experiments using a specific anti-human HIF2α antibody
confirmed the nuclear expression of the transfected con-
struct in HIF2α clones (Fig. 1c, lower panel). Untrans-BMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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fected cells (NT) or cells transfected with the empty
pCDNA3.1 vector were used as controls (C).
To confirm the activity of HIF2α and HIF2α(1–485) exog-
enous proteins, we studied the expression of tyrosine
hydroxylase (TH), a known HIF2α target gene in the sym-
pathetic nervous system [17]. We observed an increase in
TH protein expression in HIF2α clones, and a reduction in
HIF2α(1–485) compared to control cells (Fig. 1d). We
next incubated the cells in normoxia (21% O2) or in low
oxygen tension (4% O2) for 6 h and evaluated the release
of VEGF by ELISA (Fig. 1e). In controls cells, we confirmed
that VEGF expression was indeed induced, although mod-
erately, in response to decreased oxygen tension (p =
0,04). As expected, we noted a marked increase in VEGF
levels in both E1 and E2 clones, in normoxia (161% (p =
0,017) and 178% (p = 0,012) increase respectively as
compared to control cells) and in 4% O2 (117% (p =
0,004) and 272% (p < 0,001) increase respectively). In
contrast, VEGF protein concentration was not modified in
DN5 and DN8 clones in normoxia compared to control
cells, while its hypoxic induction was repressed in both
clones. Western blot evaluation of HIF1α protein levels
confirmed that the differences observed were not due to a
deregulation of HIF1α protein expression, but attributa-
ble to HIF2α transfections (Fig. 1f).
Characterization of native and transfected N1E-115 cells Figure 1
Characterization of native and transfected N1E-115 cells. a) Expression of HIF1α, HIF2α, VEGF, Neuropilin-1 (NRP-
1), adrenomedullin (ADM), neuronal-specific enolase (NSE), Id2 and Chromogranin A (CgA) as well as HIF2α endothelial-spe-
cific targets VEGFR-1, VEGFR-2 and Tie2 in N1E-115 cells and mouse kidney cDNAs. DNA ladder (L) is indicated in base pairs. 
b) Comparison of the human HIF2α (hHIF2α) 870 amino acids protein with the HIF2α(1–485) mutant shows that both activa-
tion domains have been truncated in the dominant negative form. c) Specific RT-PCR amplification of hHIF2α sequence was 
used to confirm the efficiency of transfection with both hHIF2α (E1 and E2) and hHIF2α(1–485) (DN5 and DN8) expressing 
vectors. Western blot using a specific anti-human HIF2α antibody confirmed the nuclear presence of the wild-type protein in 
E1 and E2 clones. d) Tyrosine hydroxylase (TH) expression was assessed by western blot and e) VEGF protein expression 
quantified by ELISA in duplicate 21% or 4% O2 atmosphere. Asterisks on bars illustrate statistical significance compared to NT 
cells in the same oxygen condition. Upper asterisks indicate significance between 21% and 4% O2 for each clone. f) Western 
blot evaluation of HIF1α levels revealed no variation between the different cell clones in both 21% and 4% O2.BMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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Effect of HIF2α on neuroblastoma cell phenotype
Hypoxia induces an immature phenotype of neuroblast-
oma cells [11], while inhibition of the HIF pathway by
VHL overexpression mediates differentiation toward a
neuron-like morphology [12]. We searched for such mod-
ifications in HIF2α and HIF2α(1–485) clones, but could
not detect any change in the typical cell shape nor in the
number of neuronal extension (Fig. 2a). To confirm this
observation, we studied the expression of Id2 and CgA
markers, which are respectively induced and downregu-
lated during hypoxia-mediated neuroblastoma dediffer-
entiation [11,18]. Such RT-PCR analyses revealed the
absence of any noticeable difference in their expression
between the various clones (Fig. 2b).
Unexpectedly, we observed a marked modification in
N1E-115 cell size (Fig. 2a and 2c): both HIF2α clones dis-
played an average 30% increase in cell diameter (p <
0.001), while HIF2α(1–485) cells were 15 to 25% smaller
than native or pCDNA3.1-transfected cells (p < 0.001).
We performed Western blot experiments to detect the
expression and the phosphorylation of two protein
kinases, known to play a role in the modulation of cell
size [19], i.e. Akt (Fig. 2c) and p70 s6 kinase (data not
shown). In both cases, there was no significant difference,
neither in protein expression nor in phosphorylation
between the various clones.
It is worth noting that such observations were also per-
formed on histological sections of tumour nodules grown
in vivo (see following experiments and Fig. 5) where we meas-
ured a 22% increase in cell diameter in HIF2α and a 19 %
decrease in HIF2α(1–485) nodules compared to control
ones (p < 0,001).
HIF2α reduces neuroblastoma cell growth in vitro
The other major change in cell phenotype observed was a
modification of proliferation (Fig. 3a). We indeed
observed a 44 and 51% decrease in the growth rate of
HIF2α cells in E1 (p = 0.015) and E2 (p = 0.004) clones,
respectively, while cells expressing HIF2α(1–485) grew 44
and 65% faster than controls in DN5 (p = 0.048) and
DN8 (p = 0.039) clones, respectively. During these exper-
iments, we observed no increase in cell death in HIF2α
cells compared to control or HIF2α(1–485) clones. The
differences in proliferation rates were associated with a
decrease in p42/44 mitogen activated protein kinase
(MAPK) phosphorylation in HIF2α clones, while this
pathway appeared activated in HIF2α(1–485) cells com-
pared to controls.
Effect of HIF2α on tumour growth in vivo
We then evaluated the effect of HIF2α overexpression or
inactivation in vivo in a tumourigenesis assay in syngenic
A/J mice. Cells were injected subcutaneously and the
HIF2α induces neuroblastoma cell hypertrophy Figure 2
HIF2α induces neuroblastoma cell hypertrophy. a) 
Morphology of control N1E-115 (NT), and N1E-115 trans-
fected with HIF2α and HIF2α(1–485) vectors. b) RT-PCR 
analyses of neural crest differentiation markers (Id2 and 
CgA) c) Quantification of the average cell diameter of each 
clone. Cell size data are mean ± SEM of 100 values for each 
clone, reported to 100% for NT cells. d) The difference in 
cell size was not attributable to modification in neither Akt 
protein expression nor phosphorylation as revealed by 
Western blot performed on protein extracted from the dif-
ferent clones.BMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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growth of neuroblastoma nodules evaluated over a 4-
week period (Fig. 4). As described in vitro, we observed
that both HIF2α clones and both HIF2α(1–485) clones
displayed the same behaviour, respectively. In an attempt
to limit the number of animals, we thus pooled the in vivo
data of E1 and E2 clones, now referred to as HIF2α, and
of DN5 and DN8 cells, now referred to as HIF2α(1–485).
Control cells formed regularly growing nodules, which
were stopped after 28 days, when tumours reached the
maximal volume fixed by MHI ethical guidelines. Accord-
ingly with in vitro data, we first observed a marked
decrease in the tumour growth of HIF2α overexpressing
cells when compared to controls. At day 24, the volume of
HIF2α nodules was 45% inferior to that of control
tumours (p = 0.001). However, from day 24 onward, the
growth curve of HIF2α cells displayed a marked accelera-
tion. We thus extended the evaluation period for four
HIF2α tumours. We observed that they reached the aver-
age size of 28-days control tumours 6 days after them, i.e.
at day 34.
Cells overexpressing HIF2α(1–485) did not display the
growth expected from the in vitro proliferation observa-
tions. First, they did grow slightly faster than control cells,
to reach a maximal 22% volume increase at day 19 (p =
0.058). From day 19 onward, this divergence however
diminished and at day 28, there was no distinction
between control and HIF2α(1–485) tumours volumes.
In an attempt to clarify this rather complex in vivo effect of
HIF2α on neuroblastoma growth, we removed tumours at
days 19 (just before the growth acceleration of HIF2α
nodules) and 28 for controls and HIF2α(1–485) cells and
at days 19, 28 and 35 for HIF2α nodules. Macroscopic
examination revealed that 28-days HIF2α(1–485)
tumours were pale and highly necrotic compared to con-
trols, whereas equivalent HIF2α tumours (obtained at day
35) appeared particularly dense and red coloured (Fig.
5a). These observations were confirmed by histological
observation of Masson's trichrome stained sections. Mas-
HIF2α modulates the in vivo growth of neuroblastomas Figure 4
HIF2α modulates the in vivo growth of neuroblasto-
mas. The volume of tumour nodules was measured every 2 
days after injection of control cells, HIF2α or HIF2α(1–485) 
transfected cells. Data are mean ± SEM of 15 untransfected 
tumours (NT), 16 pCDNA3.1-transfected tumours, 18 
HIF2α tumours (E1 (n = 9) and E2 (n = 9)), and 16 HIF2α(1–
485) tumours (DN5 (n = 9) and DN8 (n = 7)). Each tumour 
corresponds to one injection in one mouse.
HIF2α reduces cell proliferation Figure 3
HIF2α reduces cell proliferation. a) In vitro proliferation 
assay reveals a reduction in the relative cell proliferation rate 
of HIF2α expressing cells (E1 and E2) as compared to control 
cells (NT), while N1E-115 cells transfected with HIF2α(1–
485) display an accelerated proliferation (DN5 and DN8). 
Data are mean ± SEM of 4 independent experiments and 
reported to 100% for control untransfected cells. *: Signifi-
cant. b) Western blot analysis reveals an increased in p42/44 
MAP kinase phosphorylation in proliferating clones (DN5 
and DN8) while the opposite effect is observed in clones dis-
playing a low growth rate (E1 and E2).BMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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sive necrosis was observed in HIF2α(1–485) tumours as
compared to controls, while HIF2α nodules presented a
much-limited number of necrotic regions (Fig. 5b). At day
19, cell proliferation revealed by proliferating cell nuclear
antigen (PCNA) immunohistochemistry did not show
any difference between the 3 tumour types, which were all
actively proliferating (Fig. 5C insets). In contrast, at later
stages, we observed that within healthy-looking areas of
tumours, the number of proliferating cells was markedly
increased in both 28- and 35-days HIF2α nodules com-
pared to controls. In contrast, there was almost no PCNA
staining in cells expressing the HIF2α DN (Fig. 5c). This
observation does suggest that 28-day HIF2α(1–485)
tumours were most probably entering a regression proc-
ess, while their equivalent 35-day HIF2α counterparts
were particularly proliferating. Finally, as HIFs have been
described to induce or repress apoptosis, depending on
the cell type, we studied the number of cleaved caspase-3
positive cells, outside of the large necrotic areas. In all
tumours studied we observed isolated apoptotic cells as
well as several areas presenting an increased density of
positive cells, but we were unable to use these criteria to
discriminate between control, HIF2α and HIF2α(1–485)
tumours (Fig. 5d).
HIF2α promotes neuroblastoma angiogenesis Figure 6
HIF2α promotes neuroblastoma angiogenesis. a) Posi-
tive staining of endothelial cells in tumours was revealed by 
PECAM/CD31 immunohistochemistry and b) by Masson's tri-
chrome staining of tumour sections. Both revealed an 
increase in blood vessel density in HIF2α tumours versus 
control ones, whereas the expression of the dominant nega-
tive HIF2α(1–485) is associated with an apparent inhibition 
of the angiogenic process. c) Quantification of blood vessel 
density represents mean ± SEM of 3NT, 3 HIF2α and 4 
HIF2α(1–485) at day 19, and of 11 NT, 11 HIF2α and 6 
HIF2α(1–485) tumours and day 28.
Effect of HIF2α on tumour necrosis and late proliferation Figure 5
Effect of HIF2α on tumour necrosis and late prolifer-
ation. a) Macroscopic observations of tumour nodules and 
b) histological analyses of Masson's trichrome stained sec-
tions reveal extended necrotic areas within day 28-HIF2α(1–
485) expressing neuroblastomas, compared to control 
tumours. Such defects are less often observed up to day 35 
in HIF2α nodules. c) PCNA immunohistochemistry reveals, 
within non-necrotic regions (*), a significantly increased 
number of proliferating cells in HIF2α tumours, while 
HIF2α(1–485) neuroblastomas present very few labelled cells 
at day 28. There is no marked difference in proliferation 
between the three tumour types at day 19 (insets).BMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
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HIF2α promotes tumour angiogenesis in vivo
We hypothesized that the delayed growth of HIF2α
tumours and the simultaneous necrosis of fast-growing
HIF2α(1–485) nodules could be respectively imputable
to an increase and a defect in the angiogenic process. We
performed immunohistochemistry analyses to detect the
endothelial marker PECAM/CD31, which highlighted a
marked reduction in the vascularization of HIF2α(1–485)
expressing tumours and an amplification of angiogenesis
in HIF2α ones (Fig. 6a). Quantification of blood vessels
(Fig. 6c) within healthy regions of each tumour type
revealed that vascular density was markedly increased in
HIF2α tumours compared to controls nodules (96%
increase at day 19, p = 0.05, and 63% increase at day 28,
p = 0.006). In contrast, although angiogenesis was compa-
rable between HIF2α(1–485) nodules and control ones at
day 19, it then diminished in HIF2α(1–485) to reach a
54% decrease in the number of blood vessels compared to
control tumours at day 28 (p = 0.001).
Discussion
In the present study, we report that HIF2α promotes neu-
roblastoma cell hypertrophy and reduces their prolifera-
tion in vitro. However, we also demonstrate that in vivo, its
antiproliferation function acts in combination with an
amplification of the angiogenic process to promote the
establishment of well-structured neuroblastoma nodules.
To evaluate the role of HIF2α in neuroblastoma, we over-
expressed its native form or inactivated its function using
a DN strategy. We used the well-characterized C-terminal
deletion mutant HIF2α(1–485), which forms a het-
erodimer with ARNT, binds to the hypoxia-responsive ele-
ment (HRE) sequence but lacks the ability to transactivate
HRE-driven transcription [20,21]. In light of the parame-
ters studied, we observed reproducible and opposite
effects of HIF2α and HIF2α(1–485) respectively, and
equivalent results were obtained with two independent
clones of each transfectant. These observations strongly
argue for the efficiency and the specificity of this
approach. However, it is worth noting that HIF2α(1–485)
may also prevent HIF1α-mediated transcription [21]. In
our model, we thus cannot exclude that HIF2α(1–485)
effects may also be partly due to HIF1α inhibition.
We observed a marked effect of HIF2α on the modulation
of cell size, which was quantified in vitro as well as on his-
tological sections of tumour nodules. The impact of this
observation is still unclear, and to the best of our knowl-
edge, such an induction of neuroblastoma cell hypertro-
phy has never been reported. Interestingly, cellular
hypertrophy has been associated with cell cycle arrest in
mesangial or vascular smooth muscle cells [22,23]. HIF2α
enlarged cells also displayed a reduced proliferating rate
associated with a diminution in p42/44 MAPK phospho-
rylation, while proliferation and phospho-p42/44 were
increased in small HIF2α(1–485) cells. Although this is
the first report of an antiproliferative role of HIF2α, simi-
lar activities of HIF1α have already been described in sev-
eral cells types [4,24,25]. Consequently, these in vitro data
led us to conclude that HIF2α would present antitumoral
activities in neuroblastoma, as previously proposed in
breast cancer cells [9] and gliomas [10]. Our in vivo obser-
vations led us to reconsider this initial assumption.
We indeed show that overexpression of HIF2α leads to a
delayed growth of neuroblastoma nodules, characterized
by a well-organized structure and a homogeneous histol-
ogy 5 weeks after inoculation. In contrast, despite an
apparent acceleration in tumour growth, 4 week-old
HIF2α(1–485) neuroblastomas present extensive necrosis
associated with a marked reduction in the number of pro-
liferating cells within the apparently healthy tumour terri-
tories. Due to ethical restriction, we have not studied
HIF2α(1–485) tumours beyond this 28-day period. The
histological analysis of these tissues, together with the
PCNA immunohistochemistry data, were however sugges-
tive of a forthcoming regression, or at least growth arrest,
of neuroblastomas expressing HIF2α DN. Hence, the anti-
proliferative role of HIF2α appears to allow the favoura-
ble formation of well-organized tumour nodules instead
of reducing neuroblastoma tumourigenesis, as initially
assumed. These findings confirm the complexity of HIF2α
activity in cancer, which appears to be highly variable
depending on the cell-type. In gliomas, Acker et al.
observed a comparable negative effect of HIF2α on
tumour growth, but an exact opposite phenotype on his-
tology, with increased necrosis in HIF2α tumours and the
presence of micronecrotic areas in HIF2α-DN-expressing
ones [10].
Finally, we observed that HIF2α transfected cells led to the
formation of particularly vascularized tumours. In con-
trast, we observed that there was a clear defect in the long-
term angiogenic progression within neuroblastomas
formed by HIF2α (1–485) cells. These tumours were able
to initiate a vascularization process, but after four weeks
of growth, they presented a marked reduction in vascular
density, which could be expected to be responsible for the
growth arrest and the important necrosis we observed.
The pro-angiogenic role of HIF2α has been established in
vivo during embryogenesis [26] and in a wound healing
assay [27]. In pathological angiogenesis such a role has
been suggested by a wealth of expression studies per-
formed on tissue sections, but remained to be clarified in
experimental tumour angiogenesis. Recently, discrepant
results have been obtained in two models of ES-cells-
derived teratomas, demonstrating a positive effect of
HIF2α on vascular density [8], or an increase in vessel
diameter but no modification of blood vessel densityBMC Cancer 2007, 7:139 http://www.biomedcentral.com/1471-2407/7/139
Page 9 of 10
(page number not for citation purposes)
[10]. Our results reveal a pro-angiogenic function of
HIF2α by increasing blood vessel density in neuroblast-
oma, probably mediated by VEGF overexpression. The
long-term anti-angiogenic effect of HIF2α(1–485) dem-
onstrates that this transcription factor's endogenous activ-
ity is required for an optimal vascularization of such
tumours, putatively by improving the integrity and main-
tenance of the vascular network. These data support a very
recently published study, which reported that high HIF2α
protein levels were correlated with advanced clinical stage
and high VEGF expression and predicted poor prognosis
in a clinical neuroblastoma material [28].
Conclusion
In conclusion, this study confirms the cell-type-depend-
ent heterogeneity of HIF2α ' s  f u n c t i o n  i n  c a n c e r  a n d
reveals its unexpected antiproliferative role in the N1E-
115 neuroblastoma cell line. Instead of inhibiting cancer
progression, this function seems to act in combination
with a pro-angiogenic activity of this transcription factor
to favour the establishment of appropriately fed, well oxy-
genized, strong and thus potentially aggressive tumours.
These complementary functions, acting together, thus
emphasize a favourable role of HIF2α in neuroblastoma
tumourigenesis by providing sustained tumour growth,
albeit at a slower rate.
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